What documentation is commonly needed for GLP-1 prior authorization under Medicare?

Medicare prior authorization for GLP-1s typically requires documented proof of a type 2 diabetes diagnosis, recent lab work, and a history of failed prior therapies.

Core Requirement: A Confirmed Type 2 Diabetes Diagnosis

The most critical piece of documentation for securing a GLP-1 medication under Medicare Part D is a confirmed diagnosis of type 2 diabetes mellitus (T2DM). Medical records submitted for prior authorization must clearly show the corresponding ICD-10 code (e.g., E11.9) from a recent physician visit.

Medicare Part D plans are explicitly prohibited by law from covering drugs when used for weight loss alone. Therefore, the primary diagnosis and clinical rationale must center on glycemic control for T2DM, not on obesity or weight management.

In March 2024, CMS clarified that anti-obesity medications that also receive FDA approval for a secondary, medically necessary use may be covered. For example, Wegovy may be covered for patients with established cardiovascular disease to reduce the risk of major adverse cardiovascular events, but not for weight loss itself. This still requires a complex prior authorization.

Your physician's notes serve as the primary evidence. These notes should detail the history of the patient's diabetes, including date of diagnosis, current symptoms, and the clinical justification for prescribing a GLP-1 agonist.

Required Laboratory and Clinical Data

Prior authorization requests must be supported by recent, objective clinical data. The most important lab value is the hemoglobin A1c (HbA1c). Most plans require an A1c result from within the last 90-180 days to establish that the patient's diabetes is not adequately controlled.

While specific thresholds vary by plan, an HbA1c value above the plan's target (often >7.0% or >8.0%) is typically required to demonstrate medical necessity for escalating therapy to a GLP-1 medication. Documentation of fasting blood glucose logs may also be useful.

In addition to glycemic labs, insurers often require baseline metrics like weight, Body Mass Index (BMI), and blood pressure. These data points help establish the patient's overall metabolic health profile and serve as a baseline for measuring treatment effectiveness upon re-authorization.

Demonstrating Medical Necessity with Step Therapy

Nearly all Medicare Part D plans employ step therapy for expensive medications like GLP-1s. This policy requires patients to first try and fail one or more lower-cost, preferred medications before the plan will approve the more expensive drug.

For type 2 diabetes, plans typically require a trial of metformin, the established first-line therapy. Documentation must show the patient used metformin for a specified period (e.g., 90 days) without reaching their A1c goal, or that they had a documented intolerance or contraindication to it.

If metformin fails, plans may require a trial of a second-line agent, such as a sulfonylurea (e.g., glipizide) or a DPP-4 inhibitor (e.g., sitagliptin), before approving a GLP-1. The physician must document the failure, intolerance, or contraindication for each step.

A successful prior authorization submission meticulously chronicles this history of failed therapies, including specific drug names, dosages, trial durations, and the clinical outcomes (e.g., 'HbA1c remained at 8.5% despite max-dose metformin').

Navigating Your Specific Medicare Part D Plan Formulary

It is crucial to understand that every Medicare Part D plan has its own unique formulary (list of covered drugs) and prior authorization criteria. There is no single, universal standard across all of Medicare.

Your plan's formulary will specify which GLP-1 medications are 'preferred' or 'non-preferred.' A plan might cover Ozempic with a lower co-pay but require a higher co-pay for Trulicity, or vice-versa. Some plans may not cover certain GLP-1s at all.

To find your plan's specific requirements, you can check the plan's website for its formulary and prior authorization documents. You can also call the member services number on the back of your insurance card and ask for the criteria for a specific GLP-1 medication.

Working with a physician-supervised program can help navigate this complex landscape, as the clinical team is experienced in compiling the necessary documentation to meet the specific requirements of different insurance plans.

What if the Primary Goal Is Weight Management?

Because Medicare Part D explicitly excludes coverage for drugs used for anorexia, weight loss, or weight gain, patients seeking GLP-1s solely for weight management face significant access hurdles. A diagnosis of obesity alone is insufficient for Part D coverage.

This coverage gap leads many to seek alternative paths. For those interested in a comprehensive, physician-supervised [weight loss](/weight-loss) program that may include access to GLP-1 medications, exploring options outside of traditional Medicare Part D is often necessary.

Some Medicare Advantage (Part C) plans may offer supplemental benefits that include wellness programs or gym memberships, but direct coverage for weight loss medications remains rare. Always verify benefits directly with your specific Part C plan.

Patients may consider manufacturer patient assistance programs or direct-pay options through telehealth practices that work with licensed U.S. pharmacies to provide access to treatment when insurance is not a viable option.

Bottom Line

Successfully obtaining prior authorization for a GLP-1 medication under Medicare requires a well-documented case built on three pillars: a confirmed type 2 diabetes diagnosis, recent lab work showing poor glycemic control, and a history of failed first-line therapies.

The process is often lengthy and requires meticulous record-keeping by the prescribing physician. Patients can facilitate the process by ensuring they complete all required lab work and providing their physician with an accurate history of past medications.

For patients whose primary goal is weight loss, Medicare Part D does not provide a coverage pathway. The recent CMS guidance for cardiovascular risk reduction is a narrow exception, not a broad approval for obesity treatment.

This article is for informational purposes only and does not constitute medical advice. Consult with your healthcare provider to discuss your specific medical conditions and treatment options.

Generated from GOAL.MD's physician-reviewed source library. This page has not received its own physician review. Physician-supervised telehealth. More at goal.md/answers.